KRAS and non-small cell lung carcinoma: The CodeBreak 200 trial is an open-label, randomized, phase III study comparing the efficacy of Kras inhibitor sotorasib (experimental arm) with docetaxel (standard arm) in patients with KrasG12C-mutated advanced non-small-cell lung cancer (NSCLC) pre-treated with platinum-based chemotherapy combined with an immune checkpoint inhibitor (ICI).8